MedTrace Logo

Home OCT Guided Management Study of Subjects Diagnosed With Neovascular-AMD

NCT05650047 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 15

Last updated 2023-05-22

No results posted yet for this study

Summary

During the last 25 years, OCT has become one of the most common imaging technologies used to diagnose and monitor retinal diseases, including AMD. The OCT self-imaging capabilities of the Notal Vision Home OCT (NVHO) system for retinal fluid visualization in the central 10 degrees were validated during several prospective clinical studies1,2,3,4,5. This study is designed to evaluate the retinal fluid exposure of eyes with NV-AMD, using the NVHO system to guide therapy.

Conditions

  • Retinal Neovascularization

Sponsors & Collaborators

  • Notal Vision Inc.

    lead INDUSTRY

Principal Investigators

  • Jeff Heier, MD · Ophthalmic Consultants of Boston, Boston, MA.

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-09
Primary Completion
2023-07-26
Completion
2023-09-09

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05650047 on ClinicalTrials.gov